Wai-Sun Wong V, Ekstedt M, Lai-Hung Wong G, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842–852. https://doi.org/10.1016/J.JHEP.2023.04.036

Article  Google Scholar 

Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287–295. https://doi.org/10.1016/J.JHEP.2023.03.040

Article  PubMed  Google Scholar 

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. https://doi.org/10.1111/J.1365-2036.2011.04724.X

Article  CAS  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702. https://doi.org/10.1136/GUTJNL-2023-330595

Article  CAS  PubMed  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(S1):S47–S64. https://doi.org/10.1016/j.jhep.2014.12.012

Article  PubMed  Google Scholar 

Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. https://doi.org/10.1016/S2468-1253(20)30077-7

Article  PubMed  Google Scholar 

Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47(1):16–25. https://doi.org/10.1111/APT.14401

Article  CAS  PubMed  Google Scholar 

Tang A, Ng CH, Phang PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs Non-lean NAFLD - a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750-1760.e12. https://doi.org/10.1016/J.CGH.2022.06.029

Article  CAS  PubMed  Google Scholar 

Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Published online. 2022. https://doi.org/10.1016/J.CGH.2022.11.019

Article  Google Scholar 

Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(6): 101643. https://doi.org/10.1016/J.CPCARDIOL.2023.101643

Article  PubMed  Google Scholar 

Souza M, Diaz I, Barchetta I, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2024;44(1):6–14. https://doi.org/10.1111/LIV.15763

Article  CAS  PubMed  Google Scholar 

Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: an updated meta-analysis. Ann Hepatol. 2024;29(3):101288. https://doi.org/10.1016/J.AOHEP.2024.101288

Article  CAS  PubMed  Google Scholar 

Nso N, Mergen D, Ikram M, et al. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis. Curr Probl Cardiol. 2024;49(6):102569. https://doi.org/10.1016/J.CPCARDIOL.2024.102569

Article  PubMed  Google Scholar 

Huang S, Bao Y, Zhang N, Niu R, Tian L. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2023. https://doi.org/10.1007/S12020-023-03351-5/TABLES/3

Article  PubMed  Google Scholar 

Aboona MB, Faulkner C, Rangan P, et al. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study. Liver Int Published online. 2024. https://doi.org/10.1111/LIV.15880

Article  Google Scholar 

Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023;57(9):1014–1027. https://doi.org/10.1111/APT.17424

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78(1):272–283. https://doi.org/10.1097/HEP.0000000000000329

Article  PubMed  Google Scholar 

Lan Y, Lu Y, Li J, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun. 2022;6(12):3393–3405. https://doi.org/10.1002/HEP4.2081

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen VH, Ha A, Rouillard NA, et al. Differential mortality outcomes in real-world patients with lean, nonobese, and obese nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11(7):1448–1454. https://doi.org/10.14218/JCTH.2023.00016

Article  PubMed  PubMed Central  Google Scholar 

Wakabayashi SI, Tamaki N, Kimura T, Umemura T, Kurosaki M, Izumi N. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59(6):494–503. https://doi.org/10.1007/S00535-024-02093-Z

Article  PubMed  Google Scholar 

Ishido S, Tamaki N, Takahashi Y, et al. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2023. https://doi.org/10.1186/S12876-023-02848-7

Article  PubMed  PubMed Central  Google Scholar 

Iwaki M, Kessoku T, Tanaka K, et al. Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. JGH Open. 2022;6(10):696–703. https://doi.org/10.1002/JGH3.12808

Article  PubMed  PubMed Central  Google Scholar 

Fan X, Shi Y, Han J, Song Y, Zhao J. Beyond body weight: diversified presentation of MASLD in lean, overweight, and obese participants. J Hepatol. 2024;80(4):e147–e150. https://doi.org/10.1016/J.JHEP.2023.11.015

Article  PubMed  Google Scholar 

Zhou XD, Lonardo A, Pan CQ, et al. Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD MAFLD or Both. J Hepatol. https://doi.org/10.1016/J.JHEP.2024.03.039

Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787–788. https://doi.org/10.1001/JAMASURG.2021.0522

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https://doi.org/10.1136/BMJ.N71

Article  Google Scholar 

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/J.JHEP.2020.03.039

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. https://doi.org/10.1016/J.JHEP.2023.06.003

Article  CAS  PubMed  Google Scholar 

Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44(4):1051–1060. https://doi.org/10.1111/LIV.15856

Article  CAS  PubMed  Google Scholar 

Yang A, Zhu X, Zhang L, Ding Y. Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort. J Hepatol. 2024;80(4):e154–e155. https://doi.org/10.1016/J.JHEP.2023.09.033

Article  PubMed  Google Scholar 

McGrath S, Zhao XF, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520–2537. https://doi.org/10.1177/0962280219889080